The Canon CR-2 Digital Non-Mydriatic Retinal Camera has received U.S. Food and Drug Administration 510(k) clearance, the manufacturer announced.
Category: News
ISTA Pharmaceuticals Granted Three-Year Market Exclusivity For BROMDAY(TM)
ISTA Pharmaceuticals, Inc. , today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY(TM) (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition an…
OptiMedica’s Catalys Precision Laser System Study Shows Marked Advancement In Cataract Surgery
SANTA CLARA, Calif. – Embargoed for 2 p.m. EST, November 17, 2010 – Global ophthalmic device company OptiMedica Corp. has announced that results from a clinical study of its Catalys Precision Laser System were published in the peer-reviewed journal Sci…
Fluorescein Angiography, OCT Measurements Correlate With Visual Acuity In Eyes With DME
Fluorescein angiography, optical coherence tomography and color fundus photography showed similar associations with visual acuity in eyes treated for diabetic macular edema, a study found.
Canon Gets U.S. Approval for CR-2 Digital Retinal Camera
Canon U.S.A. has received FDA approval for its CR-2 Digital Non-Mydriatic Retinal Camera. The system accepts any Canon EOS camera, which therefore defines the exact specs of the system. Full Story →
Iris Pharma, Winner of the High Performance Prize in the Growth Category
NICE, France–(BUSINESS WIRE)–IRIS PHARMA, WINNER OF THE HIGH PERFORMANCE PRIZE IN THE GROWTH CATEGORY.
Eye Allergies Often Overlooked, Undertreated
Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. Full Story →
Online Kid’s Cataract Calculator Launched
Lens manufacturer Transitions Optical has launched a new online tool which predicts the probability of a child developing cataracts later in life. The Childrens Cataract Calculator aims to help practitioners educate parents about the importance of ch…
Novartis could stick with 77 percent stake in Alcon
Swiss drugmaker Novartis AG has not ruled out sticking with its 77 percent stake in US-listed eyecare group Alcon, Novartis chief executive Joe Jimenez was quoted as saying on Tuesday. “The intention is to have 100 per cent. But Nestle owned 77 per c…
pSivida Corp. to Present at the Maxim Group Growth Conference
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida to present at Maxim Group Growth Conference
Non-invasive Glucose Measurements In The Eye Highly Effective In Clinical Study
Freedom Meditech, Inc., the developer of non-invasive, ophthalmic-based products to detect and manage diabetes, today announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose…
Eye Allergies Often Overlooked, Undertreated – Relief Available For Millions Of Americans With Itchy, Gritty, Watery Eyes
Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. The underdiagnosis, undertrea…
Artificial retina more capable of restoring normal vision; animal study shows including retina’s neural ‘code’ improved prosthetic
Researchers have developed an artificial retina that has the capacity to reproduce normal vision in mice. While other prosthetic strategies mainly increase the number of electrodes in an eye to capture more information, this study concentrated on incor…
PRK Yields Stable Visual, Refractive Outcomes At 10 Years Despite Endothelial Cell Loss
Patients who underwent photorefractive keratectomy had stable visual quality and refraction 10 years after surgery, a study showed.
PRK Yields Stable Visual, Refractive Outcomes At 10 Years Despite Endothelial Cell Loss
Patients who underwent photorefractive keratectomy had stable visual quality and refraction 10 years after surgery, a study showed.
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-Month, Randomized, Controlled, Double-masked, Multicenter Phase II Study
Ranibizumab is investigated as a possible new treatment for diabetic macular edema (DME). Diabetes Care
Bausch + Lomb Initiates Phase 2b Study With Glaucoma Drug Candidate
NicOx S.A. today announced that its partner Bausch + Lomb has initiated a phase 2b clinical study with BOL-303259-X, previously known as NCX 116. BOL-303259-X is a nitric oxide-donating prostaglandin F2-alpha analog, which lowers intraocular pressure…
Santen Inc. Appoints Associate Director of Strategic Marketing
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals, has announced the appointment of Yuan Chang as the Associate Director of Strategic Marketing. Full Story →
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2010
WORCESTER, Mass.–(BUSINESS WIRE)–RXi Pharmaceuticals Corporation (Nasdaq: RXII) today reported its financial results for the third quarter ended September 30, 2010. RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both…
‘Know About the Glow’ Campaign Aims to Stop Deadly Eye Disease in Children by Educating Parents
LOS ANGELES–(BUSINESS WIRE)–A glow in six-year old Benjamin Webber’s eye that appeared periodically in family photographs and was mistaken as a freckle, could have led to a lifetime of blindness. Fortunately for Megan Webber, she discovered that this glow could…